Analysts are on the Bearish side about BioLineRx Ltd. (NASDAQ:BLRX) this week.

July 27, 2018 - By Victoria Pittman

BioLineRx Ltd. (NASDAQ:BLRX) Logo

BioLineRx Ltd. (NASDAQ:BLRX) Ratings Coverage

Among 2 analysts covering Biolinerx (NASDAQ:BLRX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Biolinerx had 5 analyst reports since March 6, 2018 according to SRatingsIntel. H.C. Wainwright maintained BioLineRx Ltd. (NASDAQ:BLRX) on Tuesday, March 6 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, May 22 report. The stock of BioLineRx Ltd. (NASDAQ:BLRX) earned “Buy” rating by Oppenheimer on Tuesday, March 20. The firm earned “Buy” rating on Tuesday, March 6 by Oppenheimer. On Monday, June 18 the stock rating was maintained by H.C. Wainwright with “Buy”. Below is a list of BioLineRx Ltd. (NASDAQ:BLRX) latest ratings and price target changes.

18/06/2018 Broker: H.C. Wainwright Rating: Buy New Target: $4.0000 Maintain
22/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $4.0000 Maintain
20/03/2018 Broker: Oppenheimer Rating: Buy Maintain
06/03/2018 Broker: Oppenheimer Rating: Buy New Target: $3.0 Maintain
06/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain

The stock decreased 2.87% or $0.026 during the last trading session, reaching $0.879. About 154,566 shares traded. BioLineRx Ltd. (NASDAQ:BLRX) has risen 7.06% since July 27, 2017 and is uptrending. It has underperformed by 5.51% the S&P500.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company has market cap of $94.76 million. The Company’s development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. It currently has negative earnings. The companyÂ’s other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome.

BioLineRx Ltd. (NASDAQ:BLRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.